NCT06729047View on ClinicalTrials.gov

Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

November 5, 2025

Conditions
Post-Dural Puncture Headache
Interventions
DRUG

normal Saline

patients will receive placebo (normal saline)

DRUG

Neostigmine

patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)

DRUG

Ketorolac

patients will receive ketorolac (0.5 mg/kg)

Trial Locations (1)

71515

Faculty of medicine, Assiut University, Assiut, Egypt,, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT06729047 - Prophylactic Intravenous Injection of Neostigmine Plus Atropine Versus Ketorolac on Post-dural Puncture Headache in Patients Undergoing Infraumbilical Surgeries | Biotech Hunter | Biotech Hunter